Supernus Pharmaceuticals Statistics

Total Valuation

Supernus Pharmaceuticals has a market cap or net worth of GBP 1.71 billion. The enterprise value is 1.41 billion.

Market Cap	1.71B
Enterprise Value	1.41B

Important Dates

The next estimated earnings date is Thursday, February 27, 2025.

Earnings Date	Feb 27, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-2.68%
Shares Change (QoQ)	+0.52%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	47.73M

Valuation Ratios

The trailing PE ratio is 38.41.

PE Ratio	38.41
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	6.55
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.94, with an EV/FCF ratio of 11.02.

EV / Earnings	31.76
EV / Sales	2.67
EV / EBITDA	10.94
EV / EBIT	28.67
EV / FCF	11.02

Financial Position

The company has a current ratio of 2.20, with a Debt / Equity ratio of 0.04.

Current Ratio	2.20
Quick Ratio	1.88
Debt / Equity	0.04
Debt / EBITDA	0.24
Debt / FCF	0.22
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 6.22% and return on invested capital (ROIC) is 3.80%.

Return on Equity (ROE)	6.22%
Return on Assets (ROA)	2.89%
Return on Capital (ROIC)	3.80%
Revenue Per Employee	746,068
Profits Per Employee	68,330
Employee Count	652
Asset Turnover	0.50
Inventory Turnover	0.97

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +39.90% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+39.90%
50-Day Moving Average	36.58
200-Day Moving Average	31.53
Relative Strength Index (RSI)	60.51
Average Volume (20 Days)	180

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	16.90

Income Statement

In the last 12 months, Supernus Pharmaceuticals had revenue of GBP 486.44 million and earned 44.55 million in profits. Earnings per share was 0.80.

Revenue	486.44M
Gross Profit	433.14M
Operating Income	45.35M
Pretax Income	54.08M
Net Income	44.55M
EBITDA	107.46M
EBIT	45.35M
Earnings Per Share (EPS)	0.80

Full Income Statement

Balance Sheet

The company has 300.83 million in cash and 28.47 million in debt, giving a net cash position of 272.37 million.

Cash & Cash Equivalents	300.83M
Total Debt	28.47M
Net Cash	272.37M
Net Cash Per Share	n/a
Equity (Book Value)	751.43M
Book Value Per Share	13.61
Working Capital	260.01M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 128.70 million and capital expenditures -355,144, giving a free cash flow of 128.35 million.

Operating Cash Flow	128.70M
Capital Expenditures	-355,144
Free Cash Flow	128.35M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 89.04%, with operating and profit margins of 9.32% and 9.16%.

Gross Margin	89.04%
Operating Margin	9.32%
Pretax Margin	11.12%
Profit Margin	9.16%
EBITDA Margin	22.09%
EBIT Margin	9.32%
FCF Margin	26.39%

Dividends & Yields

Supernus Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.68%
Shareholder Yield	2.68%
Earnings Yield	2.60%
FCF Yield	7.50%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Supernus Pharmaceuticals has an Altman Z-Score of 4.37.

Altman Z-Score	4.37
Piotroski F-Score	n/a